P-266: Favorable outcomes of 3-weekly daratumumab-based regimens in relapsed/refractory multiple myeloma: impact of MRD, rapid doubling time, LDH, triplets and quadruplets
Clinical Lymphoma Myeloma and Leukemia（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要